Triangle177Lu-PSMA-617 (NCT07223034)
177Lu-PSMA-617 trial for Glioma (NCT07223034). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This study is for adults with a type of glioma called IDH wild type, who have finished surgery and radiation.
The idea: carry radiation straight to the tumor cells. A radioactive medicine, lutetium-177 PSMA-617, is built to seek a protein called PSMA. The tumor sample is tested first, and only tumors that stain positive for PSMA qualify.
Patients receive two to six doses, four weeks apart, along with standard temozolomide chemotherapy, then PSMA PET and MRI scans. The study reports side effects. At Memorial Sloan Kettering in New York, Brandon Imber leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.